Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo 31P magnetic resonance spectroscopy.
This study investigates the potential of in vivo 31P magnetic resonance spectroscopy (MRS) to characterize musculoskeletal tumors and to determine preoperative levels of histological necrosis, which is an important clinical indicator of patient response. Pretherapy MRS was performed on 28 patients with large musculoskeletal tumors: 13 with osteosarcoma, 3 with chondrosarcoma, 5 with malignant fibrous histiocytoma, 1 with desmoid tumor, 1 with Ewing's, 2 with hemangioendothelioma, 1 with myxoid liposarcoma, 1 with synovial cell sarcoma, and 1 with rhabdomyosarcoma. Fifteen patients had follow-up MRS examinations after commencement of chemotherapy (mean of five/patient), eight of whom have now had surgery. Elevated levels of PMEs (P < 0.01), P(i) (P < 0.01), and PDEs (P < 0.02) as well as elevated tumor pH (P < 0.05) were observed in all patients. The synovial cell sarcoma was characterized by high levels of PMEs (> 20%) and low pH (pH 6.76). This contrasted with the spectra obtained from the malignant fibrous histiocytomas which had high levels of PDEs (17 +/- 5%). Reductions in PDE levels postchemotherapy were associated with a high degree of necrosis (> 90%) at surgery, while an increase in PDE levels was associated with a low level of histological necrosis. Likewise, reductions in the ratios PDE/NTP and PDE/PCr and an increase in P(i)/PDE were also associated with a high level of necrosis.
Redmond
O M
OM
Institute of Radiological Sciences, Dublin, Ireland.
Bell
E
E
Stack
J P
JP
Dervan
P A
PA
Carney
D N
DN
Hurson
B
B
Ennis
J T
JT
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004983:Ethanolamines / Q000032:analysis; D005260:Female; D005997:Glycerylphosphorylcholine / Q000032:analysis; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D009336:Necrosis; D009367:Neoplasm Staging; D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D012516:Osteosarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010714:Phosphatidylethanolamines / Q000032:analysis; D010725:Phosphocreatine / Q000032:analysis; D010758:Phosphorus; D010767:Phosphorylcholine / Q000032:analysis; D011300:Preoperative Care
D004983:Ethanolamines; D010714:Phosphatidylethanolamines; D010725:Phosphocreatine; D010767:Phosphorylcholine; C002449:glycerophosphoethanolamine; D010758:Phosphorus; D005997:Glycerylphosphorylcholine; C005448:phosphorylethanolamine